Progenitor Announces R&D Promotions.MENLO PARK, Calif.--(BW HealthWire)--Nov. 17, 1997--Progenitor, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :PGEN) today announced the promotion of Randall C. Schatzman, Ph.D. to Vice President, Cell and Molecular Biology Cell and Molecular Biology may refer to:
Drs. Schatzman and Wolff joined Progenitor pro·gen·i·tor n. 1. A direct ancestor. 2. An originator of a line of descent. progenitor ancestor, including parent. progenitor cell stem cells. upon the acquisition of Mercator Genetics, Inc. by Progenitor in August 1997. Progenitor also promoted Yannick Pouliot, Ph.D. to Senior Director, Bioinformatics. The three will report to H. Ralph Snodgrass, Ph.D., Vice President, Research and Chief Scientific Officer. "These promotions reflect the pivotal role of these scientists and their respective research groups in the company's ability to transform gene discoveries into commercially valuable genomics products," said Douglass B. Given, M.D., Ph.D., President and Chief Executive Officer. "Drs. Wolff and Schatzman were instrumental in the discovery of the gene for hereditary hemochromatosis Hemochromatosis Definition Hemochromatosis is an inherited blood disorder that causes the body to retain excessive amounts of iron. This iron overload can lead to serious health consequences, most notably cirrhosis of the liver. , for which a clinical lab test is now being commercialized under Progenitor's agreement with SmithKline Beecham Clinical Laboratories. Dr. Pouliot's bioinformatics leadership has enabled our gene discovery and analysis programs to function at an efficient, industrial scale." Dr. Schatzman previously served Progenitor as Executive Director of Biology. He was appointed Executive Director, Biology at Mercator in July 1996, having joined Mercator in March 1996 as Director of Molecular Biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller . Dr. Schatzman leads Progenitor's functional genomics efforts, including a therapeutic development program for anemias and other blood disorders blood disorders, n.pl hematologic dyscrasias that affect the component cells and plasma elements of the blood. They are generally divided into two broad groups: those in which an increase in bulk occurs (e.g. , based on the hereditary hemochromatosis gene discovery. Previously, Dr. Schatzman was Head of Vascular Biology at Roche Bioscience, and was Research Section Head and Director of Robotics and Laboratory Automation, Institute of Biochemistry and Cell Biology, Syntex Discovery Research. Dr. Schatzman holds a B.S. in Biochemistry from Purdue University, and M.S. and Ph.D. degrees in Molecular Pharmacology from Emory University School of Medicine. He performed his postdoctoral training under J. Michael Bishop John Michael Bishop (born February 22, 1936) is an American immunologist and microbiologist who won the 1989 Nobel Prize in Physiology or Medicine. He currently serves as an active faculty member and chancellor at the University of California, San Francisco. , M.D. at the University of California, San Francisco . Dr. Wolff previously served Progenitor as Director of Genetics. He joined Mercator as a Scientist in August, 1993, and was named Director of Genetics at Mercator in July 1996. Dr. Wolff is Project Leader for Progenitor's asthma program, which combines knowledge of both the genetics and the biology of asthma in the gene discovery process. Dr. Wolff earned a B.A. in Microbiology from the University of California, San Diego UCSD is consistently ranked among the top ten public universities for undergraduate education in the United States by U.S. News & World Report.[3] It is a Public Ivy. [1] For graduate studies, most of UCSD's Ph.D. and a Ph.D. in Human Genetics Human genetics A discipline concerned with genetically determined resemblances and differences among human beings. Technological advances in the visualization of human chromosomes have shown that abnormalities of chromosome number or structure are surprisingly from the University of Utah The University of Utah (also The U or the U of U or the UU), located in Salt Lake City, is the flagship public research university in the state of Utah, and one of 10 institutions that make up the Utah System of Higher Education. . He performed his postdoctoral training under David R. Cox, M.D., Ph.D. at the University of California, San Francisco. Dr. Pouliot joined Progenitor in March 1997 as Director of Bioinformatics. Previously, he was Senior Product Development Scientist, Bioinformatics at Molecular Simulations, Inc. Dr. Pouliot's prior genomics experience also includes positions as a biocomputational scientist at Sequana Therapeutics, Inc., and at the Gnthon human genome laboratory. Dr. Pouliot received his B.Sc., M.Sc. and Ph.D. degrees from the Department of Biology, McGill University. Progenitor applies core capabilities in developmental biology, human disease genetics and bioinformatics to discover and validate gene-based targets for the development of new pharmaceuticals. Progenitor develops and commercializes its discoveries through partnerships with biopharmaceutical companies. Except for the descriptions of historical facts contained herein, this news release contains forward-looking statements that involve risks and uncertainties as detailed from time to time in Progenitor's SEC filings under the Securities and Exchange Act of 1934, including the early stage of development of Progenitor's technology; need for additional funds; patent, regulatory and competitive risks; dependence on third parties; product liability; and other risks. CONTACT: Progenitor, Inc. Douglass B. Given, M.D., Ph.D./Mark N.K. Bagnall 650/614-7005 or Burns McClellan Audra Nass, 415/352-6262 (media) Ruth Markowitz, 212/213-0006 (investors) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion